. . . . . . . "[Patients (n = 214) with active RA (? 6 swollen and tender joints, C-reactive protein ? 10 mg/L) on oral DMARDs were randomized (2:2:1) to receive pateclizumab 360 mg, adalimumab 40 mg, or placebo subcutaneously every 2 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:44+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .